Mel Hayes

Mel Hayes

Executive Vice President, Patient AffairsatFulcrum Therapeutics· In the 2023 proxy

Pay in FY2023Fulcrum Therapeutics stock -7.3% the same year

Mel Hayes was paid $2.2M in FY2023 (Dec). Fulcrum Therapeutics stock fell 7.3% that year.

Pay$100 in the stock at the end of FY22 → $93
Pay is from the Summary Compensation Table of each Fulcrum Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Fulcrum TherapeuticsPublic company · 3 yr
    • Executive Vice President, Patient Affairs2023 – Present · 3 yrStock in role -38%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?